Alexander Ramos Guimarães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Ramos Guimarães has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
3 shared publications - Annette Kolodzie
OHSU
2 shared publications - Brett E. Johnson
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA
2 shared publications Bruce R. Rosen
Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, 02129, USA
2 shared publications- Charles D. Lopez
Oregon Health & Science University 9 Division of Hematology and Medical Oncology, Department of Medicine Portland, Oregon
2 shared publications - Christopher L. Corless
Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications
Latest Publications
- 8 October 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (37) , 2915-2925
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.
- 8 October 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (37) , 2915-2925
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.
- Open Access
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300686
Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300686
Open AccessExceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
- 24 March 2022
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 88 (1) , 151-163
3D MR fingerprinting using Seiffert spirals
Purpose: Seiffert spirals were recently explored as an efficient way to traverse 3D k‐space compared to traditional 3D techniques. Several studies have shown the ability of 3D MR fingerprinting (MRF) techniques to acquire T1 and T2 relaxation maps in a short period of time. However, these sequences do not sample across a large region of 3D k‐space every TR, especially in the way that Seiffert trajectories can.Methods: A 3D MRF sequence was designed using 8 Seiffert spirals rotated in 3D k‐space, with flip angle modulation for T1 and T2 sensitivity. The sequence was compared to an MRF sequence using a 2D spiral rotated in 3D k‐space using the tiny golden angle acquisition with similar resolution/readout duration. Both sequences were evaluated using simulations, phantom validation, and in vivo imaging.Results: In all experiments, the Seiffert spiral MRF sequence performed similar to if not better than the multi‐axis 2D spiral MRF sequence. Strong intraclass correlation coefficients (> 0.9) were found between conventional and MRF sequences in phantoms, whereas the in vivo results showed slightly less aliasing artifact with the Seiffert trajectory.Conclusion: In this study, Seiffert spirals were used within the MRF framework to acquire high‐resolution T1 and T2 relaxation time maps in less than 2.5 min. The reduced aliasing artifacts seen with the Seiffert sequence suggests that sampling over 3D k‐space evenly each TR can improve quantification or shorten scan times.
- 24 March 2022
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 88 (1) , 151-163
3D MR fingerprinting using Seiffert spirals
Purpose: Seiffert spirals were recently explored as an efficient way to traverse 3D k‐space compared to traditional 3D techniques. Several studies have shown the ability of 3D MR fingerprinting (MRF) techniques to acquire T1 and T2 relaxation maps in a short period of time. However, these sequences do not sample across a large region of 3D k‐space every TR, especially in the way that Seiffert trajectories can.Methods: A 3D MRF sequence was designed using 8 Seiffert spirals rotated in 3D k‐space, with flip angle modulation for T1 and T2 sensitivity. The sequence was compared to an MRF sequence using a 2D spiral rotated in 3D k‐space using the tiny golden angle acquisition with similar resolution/readout duration. Both sequences were evaluated using simulations, phantom validation, and in vivo imaging.Results: In all experiments, the Seiffert spiral MRF sequence performed similar to if not better than the multi‐axis 2D spiral MRF sequence. Strong intraclass correlation coefficients (> 0.9) were found between conventional and MRF sequences in phantoms, whereas the in vivo results showed slightly less aliasing artifact with the Seiffert trajectory.Conclusion: In this study, Seiffert spirals were used within the MRF framework to acquire high‐resolution T1 and T2 relaxation time maps in less than 2.5 min. The reduced aliasing artifacts seen with the Seiffert sequence suggests that sampling over 3D k‐space evenly each TR can improve quantification or shorten scan times.
- 1 January 2021
- Published by AIP Publishing
- p. 1-22
Quantitative Imaging Biomarker Alliance (QIBA): Protocols and Profiles
The practice of medicine is becoming more of a science and less of an art, and imaging science needs to keep pace in order to remain relevant. Treating physicians need and expect objective, reproducible, ideally quantitative, results from diagnostic tests, but the medical community continues to be challenged by the lack of objective, qualified imaging biomarkers useful for disease prevention, detection, and treatment. Recent advances in imaging technology present opportunities to meet these needs, but the deployment of qualified quantitative imaging biomarkers (QIBs) lags behind the technological advances. It is widely acknowledged that the primary factor limiting large-scale deployment of imaging biomarkers is the lack of standardization on how to implement them across each of the stakeholders. The current differentiation in imaging vendor products, as well as the independent activities of clinicians, individual biopharmaceutical companies, and related clinical research organizations, stands in the way of the greater opportunity that would exist if these efforts were drawn together. The formation of the Quantitative Imaging Biomarkers Alliance (QIBA) from the Radiological Society of North America (RSNA) provides a productive structure for all participants in the imaging chain to integrate activities and allow stakeholders to collaborate on the methodology to obtain QIBs. The QIBA process provides a path in the innovative development of new, promising, and objective imaging biomarkers (which benefits the imaging device industry), and innovative therapies facilitated by cost-effective, qualified biomarkers (which benefits care providers, the pharmaceutical industry, and other healthcare product providers). This chapter provides a history of QIBA from its inception, ending in a present state and challenges moving forward.
- 1 January 2021
- Published by AIP Publishing
- p. 1-22
Quantitative Imaging Biomarker Alliance (QIBA): Protocols and Profiles
The practice of medicine is becoming more of a science and less of an art, and imaging science needs to keep pace in order to remain relevant. Treating physicians need and expect objective, reproducible, ideally quantitative, results from diagnostic tests, but the medical community continues to be challenged by the lack of objective, qualified imaging biomarkers useful for disease prevention, detection, and treatment. Recent advances in imaging technology present opportunities to meet these needs, but the deployment of qualified quantitative imaging biomarkers (QIBs) lags behind the technological advances. It is widely acknowledged that the primary factor limiting large-scale deployment of imaging biomarkers is the lack of standardization on how to implement them across each of the stakeholders. The current differentiation in imaging vendor products, as well as the independent activities of clinicians, individual biopharmaceutical companies, and related clinical research organizations, stands in the way of the greater opportunity that would exist if these efforts were drawn together. The formation of the Quantitative Imaging Biomarkers Alliance (QIBA) from the Radiological Society of North America (RSNA) provides a productive structure for all participants in the imaging chain to integrate activities and allow stakeholders to collaborate on the methodology to obtain QIBs. The QIBA process provides a path in the innovative development of new, promising, and objective imaging biomarkers (which benefits the imaging device industry), and innovative therapies facilitated by cost-effective, qualified biomarkers (which benefits care providers, the pharmaceutical industry, and other healthcare product providers). This chapter provides a history of QIBA from its inception, ending in a present state and challenges moving forward.
- Open Access
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients. Highlights: Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies. Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations. Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.
Open AccessMulti-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients. Highlights: Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies. Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations. Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.
- Open Access
- 14 December 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-10
Implementing a comprehensive translational oncology platform: from molecular testing to actionability
In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was implemented. This report describes our findings to date, including the frequency with which mutational testing led to precision-guided therapy and outcome for those patients. Eligible patients presenting to Oregon Health and Science University Knight Cancer Institute were enrolled on the study. Patients with biopsy proven metastatic or locally advanced unresectable prostate cancer, breast cancer, pancreatic adenocarcinoma, or refractory acute myelogenous leukemia receiving standard of care therapy were eligible. Metastatic site biopsies were collected and analyzed using the Knight Diagnostic Lab GeneTrails comprehensive solid tumor panel (124 genes). CLIA certified genomic information was made available to the treating physician. Between 1/26/2017 and 5/30/2018, 38 patients were enrolled, with 28 successfully undergoing biopsy. Of these, 25 samples yielded sufficient tumor for analysis. The median biopsy cellularity and number of cores collected were 70% (15–90%) and 5 (2–20), respectively. No procedure-related complications occurred. GeneTrails analysis revealed that 22 of 25 (88%) tumor samples harbored at least one potentially actionable mutation, and 18 (72%) samples harbored 2 or more potentially actionable mutations. The most common genetic alterations identified involved: DNA damage repair genes, cell cycle regulating genes, PIK3CA/Akt/mTOR pathway, and FGF gene family. To date, CLIA certified genomic results were used by treating physicians for precision-guided therapy in 5 (23%) patients. We report the feasibility of real-time tissue acquisition and analysis to support a successful translational oncology platform. The workflow will provide the foundation to improve access and accrual to biomarker driven precision oncology trials.
- 14 December 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-10
Open AccessImplementing a comprehensive translational oncology platform: from molecular testing to actionability
In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was implemented. This report describes our findings to date, including the frequency with which mutational testing led to precision-guided therapy and outcome for those patients. Eligible patients presenting to Oregon Health and Science University Knight Cancer Institute were enrolled on the study. Patients with biopsy proven metastatic or locally advanced unresectable prostate cancer, breast cancer, pancreatic adenocarcinoma, or refractory acute myelogenous leukemia receiving standard of care therapy were eligible. Metastatic site biopsies were collected and analyzed using the Knight Diagnostic Lab GeneTrails comprehensive solid tumor panel (124 genes). CLIA certified genomic information was made available to the treating physician. Between 1/26/2017 and 5/30/2018, 38 patients were enrolled, with 28 successfully undergoing biopsy. Of these, 25 samples yielded sufficient tumor for analysis. The median biopsy cellularity and number of cores collected were 70% (15–90%) and 5 (2–20), respectively. No procedure-related complications occurred. GeneTrails analysis revealed that 22 of 25 (88%) tumor samples harbored at least one potentially actionable mutation, and 18 (72%) samples harbored 2 or more potentially actionable mutations. The most common genetic alterations identified involved: DNA damage repair genes, cell cycle regulating genes, PIK3CA/Akt/mTOR pathway, and FGF gene family. To date, CLIA certified genomic results were used by treating physicians for precision-guided therapy in 5 (23%) patients. We report the feasibility of real-time tissue acquisition and analysis to support a successful translational oncology platform. The workflow will provide the foundation to improve access and accrual to biomarker driven precision oncology trials.
- 4 July 2018
- Published by Elsevier in Magnetic Resonance Imaging Clinics of North America
- Vol. 26 (3) , 345-362
PET/MR Imaging of the Pancreas
- 4 July 2018
- Published by Elsevier in Magnetic Resonance Imaging Clinics of North America
- Vol. 26 (3) , 345-362
PET/MR Imaging of the Pancreas
- 1 May 2018
- Published by Elsevier in The American Journal of Surgery
- Vol. 215 (5) , 813-817
Sarcopenia is not associated with morbidity, mortality, or recurrence after esophagectomy for cancer
- 1 May 2018
- Published by Elsevier in The American Journal of Surgery
- Vol. 215 (5) , 813-817
Sarcopenia is not associated with morbidity, mortality, or recurrence after esophagectomy for cancer
- 1 July 2017
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 13 (5) , 1693-1701
Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice
- 1 July 2017
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 13 (5) , 1693-1701
Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice
- Open Access
- 1 October 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (5) , 431-437
Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma
- 1 October 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (5) , 431-437
Open AccessNoninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma